Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPACE: Psilocybin Therapy With General Anesthesia in Major Depressive Disorder
NCT07479550Phase 2Not yet recruiting
- Sponsor
- Stanford University
- Start
- Jul 2026
- Primary completion
- Jul 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of psilocybin in major depressive disorder (MDD), sponsored by Stanford University. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07479550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07479550.